Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Biotech/Pharma Business
-
By Donald Zuhn — Last summer, we reported that Roche had made an offer to acquire Ventana Medical Systems, Inc. for $75 per share, or approximately $3 billion. In response, Ventana’s Board of Directors announced that it had determined that Roche’s offer was "inadequate in multiple respects and contrary to the best interests…
-
By Christopher P. Singer — On October 30, 2007, Ocean Tomo Auctions, LLC (the auctions arm of Ocean Tomo LLC) announced the results of its live IP auction, held on October 25, 2007 in Chicago. The announcement indicated that sales from the open bidding session and transactions that immediately followed the open bidding…
-
By Christopher P. Singer — As reported last Tuesday, October 23, 2007, ARYx Therapeutics set its planned initial public offering at 5 million shares for an estimated price of $14 to $16 each. In the filing, ARYx indicated that Morgan Stanley, CIBC World Markets, Jefferies & Co, and Leerink Swann were underwriting the…
-
By Christopher P. Singer — In an August 21, 2007 press release, Ocean Tomo Auctions, LLC (the auctions arm of Ocean Tomo LLC) announced the release of its auction catalogue for its fall live IP auction, to be held on October 25, 2007. The catalogue provides information regarding the assets up for auction…
-
By Baltazar Gomez — The biotech industry needs lots of capital for research, new product development, and lots of funds for daily operations. The current trend of mergers and acquisitions in the biotech industry arises in order to satisfy the needs of the industry. Many biotech firms have promising technologies and low stock…
-
By Jason Derry — Novocell Inc. recently announced that it has received an additional $25 million in funding from a number of its stakeholders, including Johnson & Johnson Development Corp., Sanderling Ventures, Asset Management Co., and Pacific Horizon Ventures. Novocell is located in San Diego, and focuses on stem cell research. Its primary…
-
By Mark Chael — The Nasdaq Stock Market, Inc. recently announced that as part of its semi-annual re-ranking of the NASDAQ Biotechnology Index® (NBI), thirteen securities have been added to the index, while four have been dropped. All of the securities on the NBI are classified as biotech or pharma according to the…
-
By Donald Zuhn — On Thursday, Dow Chemical Co. announced that two senior executives had been fired for "engag[ing] in business activity that was highly inappropriate and a clear violation of Dow’s Code of Business Conduct." In particular, Dow determined that the two executives had been "involved in unauthorized discussions with third parties…
-
By Donald Zuhn — On the heels of last weekend’s report that a consortium of Middle Eastern investors and American buyout firms was preparing to pull off the world’s biggest leveraged buyout – a $50 billion buyout of Dow Chemical Co., Dow countered today that it has had no discussions concerning a leveraged…
-
By Donald Zuhn — On March 23, 2007, Simcere Pharmaceuticals filed a registration statement with the Securities and Exchange Commission (SEC) for a proposed initial public offering of its common stock. According to a MarketWatch report, the Chinese generic drug maker is seeking to raise $120 million in the IPO. Simcere’s shares will…
Patent Docs 